Teva Wins Appeal Over Generic Tirosint Thyroid Drug

A trial court was correct to invalidate a patent owned by IBSA Institut Biochimique and Altergon for a formulation for thyroid hormones, U.S. Court of Appeals for the Federal Circuit ruled Friday in a victory for Teva.

• Teva is looking to sell a generic version of the treatment
• Tirosint is a soft gel capsule formulation containing the active ingredient levothyroxine sodium, but the patent was unclear, three-judge panel ruled
• Docket link

To contact the reporter on this story:
Susan Decker in Washington at sdecker1@bloomberg.net

To contact the editors responsible for this story:
Jon Morgan at jmorgan97@bloomberg.net

Susan Decker

© 2020 ...